AstraZeneca Records $4-Billion By Covid-19 Vaccine Sales as Revenue Increases

The company ‘AstraZeneca’ has recorded a big increase in the revenue on Thursday, 10^th February 2022, as the company has now started to take a profit from the company’s novel corona virus for the first time, and the company has also recorded complete year revenues of 37.4 billion dollars, which has been an increase of 38 percent at the constant exchange rates.

In spite of increasing the revenue, the company AstraZeneca has also reported a loss of 265 million dollars pre-tax because of the costs from the purchase of the United States based company known as Alexion Pharmaceuticals and also a new drug research. The other novel corona virus vaccine developers like Moderna and Pfizer have now been booking the heavy profits on the vaccine shots of the companies all along.

The company said that, the revenue has been increased by around 50 percent to a record of 9.9 billion dollars, and this increase had been because of the sales of over one billion dollars in the novel corona virus vaccines and this inclusion has been made for the first time of around 1.3 billion dollar worth of the revenue from the company’s rare disease business unit followed by the acquisition of Alexion.

Pascal Soriot, chief executive of AstraZeneca said that, the company has now delivered on the promise made by the company of broadening and accessing the corona virus vaccine with 2.5 billion shots released for supply across the world.